Revista espanola de medicina nuclear e imagen molecular最新文献

{"title":"Radioactive seed localization technique with 125-I in inguinal endometriosis","authors":"L. Rodríguez-Díaz , E. García , C. de Guirior , R. Salvador , J. Ribera-Perianes , S. Vidal-Sicart","doi":"10.1016/j.remnie.2024.500069","DOIUrl":"10.1016/j.remnie.2024.500069","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500069"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of staging using [68Ga]Ga-PSMA-11 PET/CT and histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection","authors":"J.J. Rosales ,&nbsp;V. Betech Antar ,&nbsp;F. Mínguez ,&nbsp;F. Pareja ,&nbsp;F. Guillén ,&nbsp;E. Prieto ,&nbsp;G. Quincoces ,&nbsp;F.D. Caballero ,&nbsp;B. Miñana ,&nbsp;J.L. Pérez-Gracia ,&nbsp;M. Rodríguez-Fraile","doi":"10.1016/j.remnie.2024.500076","DOIUrl":"10.1016/j.remnie.2024.500076","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the diagnostic accuracy of [⁶⁸Ga]Ga-PSMA-11 PET/CT (PET-PSMA) in local and loco-regional nodal staging compared with histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy (RP) and pelvic lymph node dissection (PLND).</div></div><div><h3>Materials y methods</h3><div>A total of 122 intermediate- and high-risk prostate cancer (PCa) patients staged with PET-PSMA and treated with RP (36/122) and RP plus PLND (86/122) from December 2018 to December 2023 were included. Visual and semiquantitative analysis findings using the SUVmax of the molecular imaging were correlated with histopathological results.</div></div><div><h3>Results</h3><div>The primary tumor was visible by PET-PSMA in 96.7% of the patients. A positive correlation was found between PSA levels and SUVmax (Spearman’s r: 0.303, p &lt; 0.001). PET-PSMA detected nodal involvement in 25/89 patients (28.08%). The sensitivity, specificity, and diagnostic accuracy of PET-PSMA for detecting nodal involvement were 75%, 82.2%, and 80.9%, respectively. Patients with PSA levels &gt;20 ng/mL, Gleason score ≥7b, ISUP grade &gt;2, and extracapsular extension showed significantly higher SUVmax values. No differences were observed in SUVmax between risk groups or in other histopathological variables.</div></div><div><h3>Conclusions</h3><div>PET-PSMA is an effective tool for the initial staging of intermediate- and high-risk PCa. SUVmax values were significantly higher in patients with unfavorable clinical features.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500076"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of 18F-FDG PET/CT in the diagnosis and grading of incidental colorectal adenomas","authors":"Z. Qi ,&nbsp;K. Tang ,&nbsp;X. Lu ,&nbsp;Y. Zhu ,&nbsp;N. Xu","doi":"10.1016/j.remnie.2024.500075","DOIUrl":"10.1016/j.remnie.2024.500075","url":null,"abstract":"<div><h3>Purpose</h3><div>Colorectal adenomas (CRAs) are at a higher risk of progressing to colorectal cancer (CRC) as their histological grade increases. Herein, this study investigated the relationship between the maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography-computed tomography (¹⁸F-FDG PET/CT) and the histological grades of CRAs and constructed the optimal regression model for distinguishing between different histological grades.</div></div><div><h3>Methods</h3><div>This study retrospectively analyzed the data of 153 patients with CRAs who had colorectal ¹⁸F-FDG uptake incidentally found on PET/CT. The patients were categorized into low-grade intraepithelial neoplasia (LGIN) and high-grade intraepithelial neoplasia (HGIN) groups based on their histological grade. After the analysis of the relationship between SUVmax measured on preoperative ¹⁸F-FDG PET/CT scans and histological grades, receiver-operating characteristic (ROC) curves were analyzed to determine the optimal cut-off values for distinguishing between the two groups. Common clinical and pathological factors were included and subjected to univariate and multivariate logistic regression analyses to identify independent risk factors. A diagnostic model integrating SUVmax and several risk factors was developed with the multivariate logistic regression analysis.</div></div><div><h3>Results</h3><div>SUVmax was significantly different between the two groups (<em>P</em> &lt; 0.001) and increased with an elevation in the malignancy degree. The area under the ROC curve (AUC) for identifying LGIN and HGIN was 0.796, and the AUC of the combination model was 0.822. Furthermore, SUVmax was an independent risk factor for distinguishing between different histological grades in pairwise comparisons.</div></div><div><h3>Conclusion</h3><div>The regression model involving SUVmax on ¹⁸F-FDG PET/CT can distinguish between histological grades of CRAs, which therefore can be used as a noninvasive tool for the accurate diagnosis of CRAs and assist in developing patient-specific treatment strategies before surgery.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500075"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142634080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role and applications of [18F]FDG PET/CT in the assessment of osteoarticular infection and inflammation — Part II","authors":"E. Noriega-Álvarez ,&nbsp;B. Rodríguez Alfonso ,&nbsp;J.J. Rosales Castillo ,&nbsp;A. Moreno Ballesteros ,&nbsp;E. López Rodríguez ,&nbsp;S. Sanz Viedma ,&nbsp;M.P. Orduña Diez ,&nbsp;L. Domínguez Gadea","doi":"10.1016/j.remnie.2025.500102","DOIUrl":"10.1016/j.remnie.2025.500102","url":null,"abstract":"<div><div>[¹⁸F]FDG PET/TC is an emerging tool in the evaluation of inflammatory arthropathies, characterised by their insidious course and clinical overlap. It allows detection of subclinical inflammation, assessment of systemic involvement and quantification of metabolic parameters useful in early diagnosis and therapeutic monitoring. In rheumatoid arthritis, it correlates with clinical indices (<em>Disease Activity Score</em>), serological markers (CRP, anti-citrullinated protein antibodies) and ultrasound findings, and facilitates the identification of complications such as cardiovascular and pulmonary involvement. In spondyloarthritis, its ability to identify enthesitis and peripheral synovitis is promising, although less studied. In addition, [¹⁸F]FDG PET/TC evaluates the response to biological treatments, helping to optimise therapeutic decisions. However, its implementation faces challenges such as lack of standardised indications, incidental findings and technical artefacts. Although not routinely recommended, its usefulness in specific settings underlines the need for further studies to consolidate its role in the management of these diseases. In this manuscript, we present a brief review providing general and practical information about the role of [¹⁸F]FDG PET/TC in inflammatory osteoarticular pathology, while “Role and applications of [¹⁸F]FDG PET/CT in the assessment of osteoarticular infection and inflammation — Part I” has addressed its role in infectious osteoarticular disease.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500102"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome and incidence of hypothyroidism in low-dose radioactive iodine treatment for hyperthyroidism","authors":"Ku-Hung Lin ,&nbsp;Jiun-Chang Wu ,&nbsp;Ming-Che Wu","doi":"10.1016/j.remnie.2024.500056","DOIUrl":"10.1016/j.remnie.2024.500056","url":null,"abstract":"<div><h3>Objective</h3><div>The study aimed to analyze the outcome of low-dose radioactive iodine (RAI) treatment for hyperthyroidism, disclose whether age and gender influence the outcome and determine the incidence and onset time of hypothyroidism following low-dose RAI.</div></div><div><h3>Material and methods</h3><div>A total of 158 patients who received doses less than 370 Mbq RAI were enrolled in the study. Treatment outcome and incidence of hypothyroidism were compared between different gender (45 male vs.113 female), age (77 patients ≥45 years old vs. 81 patients &lt;45 years old) and dose (39 patients receiving higher doses RAI vs. 119 receiving lower dose with a cutoff of 222 MBq) groups. Treatment outcomes were categorized into post-treatment hypothyroidism, treatment failure (persistent hyperthyroidism), and euthyroidism. In those becoming hypothyroid, time to develop hypothyroidism was calculated for cumulative incidences over time.</div></div><div><h3>Results</h3><div>Out of 158 patients, 47 (29.7%) developed hypothyroidism, 101 (63.9%) had treatment failure, and 10 (6.3%) remained euthyroid after treatment. Response rates (33.6% vs. 43.5%, p = 0.260) and hypothyroidism incidences (26.9% vs. 38.5%, p = 0.170) did not differ significantly between lower and higher dose groups, neither between lower and higher age groups (p = 0.69 in response rates and p = 0.75 in hypothyroidism incidence). Females exhibited higher response rates (42.5% vs. 20.0%, p = 0.008) and hypothyroidism incidence (46.3% vs. 13.3%, p = 0.004) compared to males. Hypothyroidism onset occurred at a mean of 24.0 ± 29.2 months, and the cumulative incidences over time were 47% and 60% in six and twelve months, respectively.</div></div><div><h3>Conclusions</h3><div>Low-dose RAI has a low response rate for treating hyperthyroidism. Although there may be a lower incidence of hypothyroidism following low-dose RAI compared to high-dose RAI, hypothyroidism may occur early after treatment. Besides, females have higher response rates but more incidence of hypothyroidism. The balance between the risks and benefits of using low-dose RAI should be taken into deliberate consideration.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 2","pages":"Article 500056"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: The role of baseline volumetric 18F-FDG PET/CT parameters and inflammatory markers","authors":"Gokmen Umut Erdem ,&nbsp;Ozge Vural Topuz ,&nbsp;Esranur Acar ,&nbsp;Tanju Kapagan ,&nbsp;Esma Yetim ,&nbsp;Aykut Ozmen ,&nbsp;Simay Gurocak ,&nbsp;Gamze Usul ,&nbsp;Sercan Yuksel ,&nbsp;Aytul Hande Yardimci ,&nbsp;Nilufer Bulut","doi":"10.1016/j.remnie.2025.500113","DOIUrl":"10.1016/j.remnie.2025.500113","url":null,"abstract":"<div><h3>Objectives</h3><div>We evaluated the influence of baseline volumetric 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) parameters and inflammatory prognostic markers on complete response (CR) in patients with locally advanced rectal cancer<span> (LARC) treated with neoadjuvant chemoradiotherapy (nCRT).</span></div></div><div><h3>Materials and Methods</h3><div>In total, 90 patients with LARC, including those with and without CR, were evaluated based on baseline volumetric PET/CT parameters, such as maximum standard uptake value, metabolic tumor volume (MTV), tumor lesion glycolysis, and inflammatory prognostic markers, including the lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio.</div></div><div><h3>Results</h3><div>Of the 90 patients, 62 (68.9%) were male and 28 (31.1%) were female. The median age was 61 (31–81) years. A complete response was observed in 20 (22%) patients following nCRT. Of these, 5 demonstrated a clinical complete response, whereas 15 exhibited a complete response after surgery. A low pretreatment PLR, low MTV levels, and stage 2 disease were identified as significant predictors of complete response. The optimal cutoff values were 16.5 for MTV (sensitivity 80%, specificity 62%) and 121 for PLR (sensitivity 73%, specificity 65%).</div></div><div><h3>Conclusion</h3><div>Our findings suggest that stage 2 disease, low pretreatment MTV, and low PLR levels may be predictive of a CR to nCRT in patients with LARC.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 5","pages":"Article 500113"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel heterogeneity method for predicting survival in non-metastatic triple-negative breast cancer","authors":"G.B. Babacan ,&nbsp;M. Öner Tamam ,&nbsp;S. Saraçoğlu ,&nbsp;M.N. Acar Tayyar ,&nbsp;M.C. Şahin ,&nbsp;H. Özçevik ,&nbsp;G. Kulduk ,&nbsp;Ö.B. Ekinci ,&nbsp;E. Çelik","doi":"10.1016/j.remnie.2025.500112","DOIUrl":"10.1016/j.remnie.2025.500112","url":null,"abstract":"<div><h3>Objective</h3><div><span>This study aimed to investigate the relationship between semiquantitative positron emission tomography (PET) parameters and intratumoral heterogeneity (ITH) on </span>¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) imaging and survival data of non-metastatic triple-negative breast cancer (TNBC) patients.</div></div><div><h3>Methods</h3><div>Sixty-two consecutive female patients who underwent pretreatment ¹⁸<span>F-FDG PET/CT with non-metastatic TNBC were enrolled. Heterogeneity index<span> (HI) variables derived from the metabolic tumor volume<span> (MTV) and standardized uptake value (SUV) parameters of primary lesions were evaluated. A novel modified method introducing a percentage-based (30–40–50%) MTV slope comparison was proposed. The association between conventional </span></span></span>¹⁸F-FDG PET/CT parameters, HI values, and survival results was analyzed retrospectively.</div></div><div><h3>Results</h3><div><span>Tumors with higher HI values were associated with shorter survival times<span>. For overall survival (OS), HI2 and HI3 were statistically significant (</span></span><em>p</em> <!-->=<!--> <!-->0.009, <em>p</em> <!-->=<!--> <!-->0.016). Regarding radiological progression-free survival (rPFS), HI1 and HI3 were statistically significant (<em>p</em> <!-->=<!--> <!-->0.01, <em>p</em> <!-->=<!--> <!-->0.025). A significant weak correlation between HI1 (<em>p</em> <!-->=<!--> <!-->0.005, <em>ρ</em> <!-->=<!--> <!-->0.34) and a strong correlation was found for HI2 (<em>p</em> <!-->&lt;<!--> <!-->0.0001, <em>ρ</em> <!-->=<!--> <!-->0.89), HI3 and tumor size were not statistically significantly correlated (<em>p</em> <!-->=<!--> <!-->0.063, <em>ρ</em> <!-->=<!--> <!-->0.23). T stage was statistically significantly associated with rPFS and OS ((<em>p</em> <!-->=<!--> <!-->0.038, <em>p</em> <!-->=<!--> <!-->0.003). In contrast, no statistically significant difference was found for the N stage, anatomical, and clinical staging (<em>p</em> <!-->&gt;<!--> <!-->0.05).</div></div><div><h3>Conclusion</h3><div>This study concluded that ITH predicts survival for non-metastatic TNBC patients. This conclusion was reached with the heterogeneity index variables obtained by different methods. However, our results revealed that HI2 depends on tumor size. Our modified method (HI3) predicts survival independently of tumor size.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 5","pages":"Article 500112"},"PeriodicalIF":0.0,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluación de la fiabilidad y legibilidad de las respuestas de los chatbots como recurso de información al paciente para las exploraciones PET-TC más communes","authors":"N. Aydinbelge-Dizdar ,&nbsp;K. Dizdar","doi":"10.1016/j.remnie.2024.500065","DOIUrl":"10.1016/j.remnie.2024.500065","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to evaluate the reliability and readability of responses generated by two popular AI-chatbots, ‘ChatGPT-4.0’ and ‘Google Gemini’, to potential patient questions about PET/CT scans.</div></div><div><h3>Materials and methods</h3><div>Thirty potential questions for each of [¹⁸F]FDG and [⁶⁸Ga]Ga-DOTA-SSTR PET/CT, and twenty-nine potential questions for [⁶⁸Ga]Ga-PSMA PET/CT were asked separately to ChatGPT-4 and Gemini in May 2024. The responses were evaluated for reliability and readability using the modified DISCERN (mDISCERN) scale, Flesch Reading Ease (FRE), Gunning Fog Index (GFI), and Flesch-Kincaid Reading Grade Level (FKRGL). The inter-rater reliability of mDISCERN scores provided by three raters (ChatGPT-4, Gemini, and a nuclear medicine physician) for the responses was assessed.</div></div><div><h3>Results</h3><div>The median [min-max] mDISCERN scores reviewed by the physician for responses about FDG, PSMA and DOTA PET/CT scans were 3.5 [2–4], 3 [3–4], 3 [3–4] for ChatPT-4 and 4 [2–5], 4 [2–5], 3.5 [3–5] for Gemini, respectively. The mDISCERN scores assessed using ChatGPT-4 for answers about FDG, PSMA, and DOTA-SSTR PET/CT scans were 3.5 [3–5], 3 [3–4], 3 [2–3] for ChatGPT-4, and 4 [3–5], 4 [3–5], 4 [3–5] for Gemini, respectively. The mDISCERN scores evaluated using Gemini for responses FDG, PSMA, and DOTA-SSTR PET/CTs were 3 [2–4], 2 [2–4], 3 [2–4] for ChatGPT-4, and 3 [2–5], 3 [1–5], 3 [2–5] for Gemini, respectively. The inter-rater reliability correlation coefficient of mDISCERN scores for ChatGPT-4 responses about FDG, PSMA, and DOTA-SSTR PET/CT scans were 0.629 (95% CI = 0,32−0,812), 0.707 (95% CI = 0.458−0.853) and 0.738 (95% CI = 0.519−0.866), respectively (p &lt; 0.001). The correlation coefficient of mDISCERN scores for Gemini responses about FDG, PSMA, and DOTA-SSTR PET/CT scans were 0.824 (95% CI = 0.677−0.910), 0.881 (95% CI = 0.78−0.94) and 0.847 (95% CI = 0.719−0.922), respectively (p &lt; 0.001). The mDISCERN scores assessed by ChatGPT-4, Gemini, and the physician showed that the chatbots' responses about all PET/CT scans had moderate to good statistical agreement according to the inter-rater reliability correlation coefficient (p &lt; 0,001). There was a statistically significant difference in all readability scores (FKRGL, GFI, and FRE) of ChatGPT-4 and Gemini responses about PET/CT scans (p &lt; 0,001). Gemini responses were shorter and had better readability scores than ChatGPT-4 responses.</div></div><div><h3>Conclusion</h3><div>There was an acceptable level of agreement between raters for the mDISCERN score, indicating agreement with the overall reliability of the responses. However, the information provided by AI-chatbots cannot be easily read by the public.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 1","pages":"Article 500065"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response, complications and risk of leukemic transformation of phosphorus-32p treatment in philadelphia-negative chronic myeloproliferative syndromes","authors":"I. Tobalina Larrea ,&nbsp;J. Cuetos Fernández ,&nbsp;A. Mendizabal Abad ,&nbsp;A. Montero de la Peña ,&nbsp;D. García Hernández ,&nbsp;G.H. Portilla Quatrociocchi ,&nbsp;M. Jiménez Alonso ,&nbsp;M.C. Menchaca Echevarria","doi":"10.1016/j.remnie.2024.500064","DOIUrl":"10.1016/j.remnie.2024.500064","url":null,"abstract":"<div><h3>Objective</h3><div>Describe our experience in treatment with Phosphorus-32P for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.</div></div><div><h3>Material and methods</h3><div>Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with Phosphorus-32P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.</div></div><div><h3>Results</h3><div>Of the 17 patients treated with 32P (11 men, 6 women; mean age 79,8 years), 6 patients had Polycythemia Vera and 11 Essential Thrombocytosis. A single dose was administered in 9 of the subjects, the rest required two or more doses due to inadequate hematological response and/or relapse. The total dose range of Phosphorus-32P administered was 116−951<!--> <!-->MBq (median: 236<!--> <!-->MBq). In 14 patients treated with Phosphorus-32P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count &lt;400.000/mm³ in those diagnosed with Essential Thrombocythemia and a hematocrit &lt;45% in cases of Polycythemia Vera. The median follow-up of patients from the date of the first treatment of Phosphorus-32P until study completion or death was 37 months (range: 5–230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and 1 case of mild thrombocytopenia. No leukemic transformation was identified.</div></div><div><h3>Conclusions</h3><div>In our experience, treatment with Phosphorus-32P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 1","pages":"Article 500064"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET-TC [18F]F-choline and intraoperative PTH in the surgical treatment of the primary hyperparathyroidism without preoperative location","authors":"F. García García ,&nbsp;N. Cassinello Fernández ,&nbsp;J. Rodríguez Romera ,&nbsp;R. Martí Fernández ,&nbsp;M. Lapeña Rodríguez ,&nbsp;R. Alfonso Ballester ,&nbsp;R. Díaz Expósito ,&nbsp;J. Ortega Serrano","doi":"10.1016/j.remnie.2024.500066","DOIUrl":"10.1016/j.remnie.2024.500066","url":null,"abstract":"<div><h3>Background and objectives</h3><div>To assess the feasibility of performing selective parathyroidectomy without intraoperative parathyroid hormone (PTHio) determination when first-line preoperative localization tests (ultrasonography and [^99mTc]Tc-MIBI) are negative and/or discordant, and second-line [¹⁸F]F-Colina PET-CT, is positive.</div></div><div><h3>Materials and methods</h3><div>Retrospective cohort study, including patients with negative or discordant ultrasound and MIBI scans and positive [¹⁸F]F-Colina PET-CT, who underwent selective parathyroidectomy between 2019 and 2022. Groups were compared based on PTHio determination. Study variables were: gender, mean age, biochemical cure assessed by PTH value (pg/mL) and corrected calcium by albumin (mg/dL) at 6 months post-surgery follow-up, and histopathological analysis.</div></div><div><h3>Results</h3><div>The final sample included 42 patients. At 6 months post-surgery, in the PTHio group (20 patients), PTH values were 64.50 pg/mL and calcium 9.30 pg/mL, with 19 adenomas and 1 hyperplasia found. In the non-PTHio group (22 patients), PTH values were 61 pg/mL and calcium 9.37 pg/mL, with 22 adenomas found. No statistically significant differences were found between both groups.</div></div><div><h3>Conclusions</h3><div>Based on the results obtained in our patient cohort, selective parathyroidectomy could be considered with negative or discordant first-line tests and positive [¹⁸F]F-Colina PET-CT, without intraoperative PTH determination.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 1","pages":"Article 500066"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}